FindTrial
Sign In

bb2121

BIOLOGICAL7 trials

Sponsors

Celgene, Medical College of Wisconsin

Conditions

Multiple Myeloma

Phase 1

Study of bb2121 in Multiple Myeloma
CompletedNCT02658929
CelgeneMultiple Myeloma
Start: 2015-12-22End: 2022-09-22Updated: 2023-01-23
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
CompletedNCT04196491
CelgeneMultiple Myeloma
Start: 2020-05-27End: 2023-06-07Updated: 2023-08-23
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
TerminatedNCT04855136
CelgeneMultiple Myeloma
Start: 2021-06-01End: 2025-04-25Updated: 2025-09-11

Phase 2

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
CompletedNCT03361748
CelgeneMultiple Myeloma
Start: 2017-12-13End: 2023-12-20Updated: 2025-05-23
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
CompletedNCT03601078
CelgeneMultiple Myeloma
Start: 2018-12-13End: 2026-01-15Updated: 2026-03-04
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
CompletedNCT05032820
Medical College of WisconsinMultiple Myeloma
Start: 2022-01-05End: 2025-02-20Updated: 2026-05-19

Phase 3

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Active, not recruitingNCT03651128
CelgeneMultiple Myeloma
Start: 2019-04-16End: 2027-04-08Updated: 2022-12-15

Related Papers

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation
Blood2025-11-03
Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial
Blood2025-11-03
KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel
Blood2025-11-03
Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma
British Journal of Haematology2025-07-151 citations
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma
The Journal of Clinical Pharmacology2025-07-10
Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
2025-06-031 citations
Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).
Journal of Clinical Oncology2025-05-281 citations
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Blood2025-04-088 citations
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Blood2024-11-054 citations
Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma
Blood2024-11-051 citations
Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
Blood2024-11-051 citations
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Blood2024-08-2846 citations
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.
Journal of Clinical Oncology2024-06-012 citations
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
Journal of Clinical Oncology2024-06-01
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology2024-04-232 citations
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
2024-03-0122 citations
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
Blood2023-11-0215 citations
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Blood2023-11-0211 citations
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3
Blood2023-11-025 citations
Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial
Blood2023-11-023 citations

76 more papers not shown